1167 COST BENEFIT ANALYSIS OF RESPONSE GUIDED THERAPY: DYNAMIC DISEASE MARKOV MODELING FOR PATIENTS WITH CHRONIC HEPATITIS (HCV) BY FIBROSIS STAGES | Publicación